



Prof. Dr. Metin BASARANOGLU

Prof in Gastroenterology

Prof in Hepatology

CURRENT CLINICAL AND RESEARCH WORK ADDRESS:

Office : Division of Gastroenterology and Hepatology

Department of Internal Medicine

Bezmialem Vakif University

Adnan Menderes Bulvari, Vatan Caddesi, Fatih

Istanbul, Turkey

E-mail: metin_basaranoglu@yahoo.com

EDUCATION AND TRAINING:

- Istanbul University Medical Faculty, Istanbul, Turkey
- Internship and Residency, Internal Medicine, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey
- Fellow in Gastroenterology/Hepatology, Turkey and SLU Liver Center, St. Louis University Hospital, MO, USA
- Gastroenterology Clinical Fellow, Middlesex Hospital, London, UK
- Hepatology Clinical Fellow, Mount Sinai School of Medicine, NY, USA
- passed ECFMG- USMLE, permanent
- Echoendoscopy fellow: Roma Catholic University, Policlinico Gemelli, Italy.
- RF ablation and Fibroscan training fellow in Bologna, Italy
- Advanced Endoscopy fellow and i-scan PENTAX endoscopy in Vienna

Short Biography

- Professor received his MD from Istanbul University. He completed his postdoctoral studies in St. Louis University School of Medicine/Liver Centre, St. Louis/MO, USA.
- He studied particularly in fatty liver disease, viral hepatitis, inflammatory bowel diseases (crohn's and chronic ulcerative colitis) biology and therapeutics for 20+ years, during which time he has authored more than 100 peer-reviewed research articles and one book chapter and one book/published in NY 2008 and 2009.
- Currently, Prof. Conducted 7 phase 3 clinical trials: 2 NAFLD FATTY LIVER and 5 Inflammatory Bowel Diseases, crohn's and CUC.
- He performed basic science research, animal research in NAFLD&NASH. MO, St. Louis, USA.
- He has served on the editorial boards for the journals and referee for "Gastroenterology", "Hepatology", and The American Journal of Gastroenterology.
- He is a member of The American Association for the Study of Liver Diseases (AASLD) and The European Association for the Study of the Liver (EASL).
- He was awarded twice by AASLD (1998/2002), once by EASL (2009) and once by FALK, Germany 2010.
- His main research areas: Inflammatory bowel disease (IBD), nonalcoholic fatty liver disease/NAFLD, echoendoscopy (EUS), advanced endoscopic procedures, RF ablation for HCC and fibroscan

MEDICAL LICENSURE: USA, Turkey

SOCIETIES AND MEMBERSHIPS:

- The American Association for the Study of Liver Diseases (**AASLD**).

- The European Association for the Study of the Liver (**EASL**)

HONORS, AWARDS AND CERTIFICATIONS:

- *The American Association for the Study of Liver Diseases (AASLD). Chicago, USA. **Young Investigator Award***
- *Atlanta, USA. **Young Investigator Award***
- Bronz medal. European Respiratory Society. Denmark.
- *The European Association for the Study of the Liver (EASL). Italy. **Short-Term Research Fellowship, 3 months.***
- *Silver Medal, Falk Organization. Germany.*
- Monothematic Conference in Primary Biliary Cirrhosis. Milan. Italy
- EASL Austria, Title : NAFLD associated cirrhosis

PROFESSIONAL SERVICE:

Organizer of 1. International T.C. Ankara Yildirim Beyazit University Echoendoscopy Days-Conference. Speakers: Claudio De Angelis (Italy), Marc Givonnini (France), Vanessa Shami (USA). I was the general secretary of the Conference. November 2011

ACADEMIC ACTIVITIES:

Editorial board:

1. World Journal of Gastroenterology
2. Journal of Liver.
3. International scholarly research network.
4. Journal of Gastroenterology and Hepatology Research.
5. European Journal of General Medicine

Ad hoc reveiwer:

1. Gastroenterology
2. Hepatology
3. American Journal of gastroenterology
4. Clinical Gastroenterology and Hepatology
5. World Journal of Gastroenterology
6. Dig Dis of Sci
7. Journal of the pancreas
8. Turkish Journal of Gastroenterology

MAJOR INVITED INTERNATIONAL TALKS:

2015 EASD/NAFLD working group, New Castle, UK.

- Gastrointestinal Cancers: The UEG Basic Science Course. Munich, Germany.
- Liver Cancers. 1. Targeting Liver Diseases. Jerusalem, Israel.

2012 Epitelial ion transport in the GI tract. UEG education. Basic Science. Hungary.

2011 Hepatic fibrosis in animal models. Fibrosis in the GI tract. UEGF Teaching activity. Basic Science. Italy.

2005 Conference: Insulin resistance in NASH. St. Louis University Hospital, St. Louis, MO, USA

INTERNATIONALLY PUBLISHED BOOK AND BOOK CHAPTERS

PUBLISHED BOOK CHAPTER. 2008, NY, ABD

Basaranoglu M and Neuschwander-Tetri Brent. Metabolic Aspects of Chronic Liver Diseases. Chapter 1: Pathophysiology of NASH. 2008. Nova Science. NY. USA.

PUBLISHED BOOK. 2009, NY ABD

Basaranoglu M and Neuschwander-Tetri Brent. Pathophysiology of Nonalcoholic Steatohepatitis. 2009. Nova Science. NY. USA.

ORIGINAL RESEARCH ARTICLES-PUBLISHED

NAFLD: 1,3,4,6,11,14,16

IBD:5,7,9

PANCREAS:2,12,13

HEPATITIS B AND C:8,10,15

SARCOIDOSIS:18-21

1. **Basaranoglu M**, Najjar SM, Demirbag AE, Senturk H. Significant cohort of non-alcoholic fatty liver disease with portal vein thrombosis in transplant waiting list. *World J Hepatol.* 2016 Mar 8;8(7):376-84. doi:10.4254/wjh.v8.i7.376. PubMed PMID: 26981175; PubMed Central PMCID: PMC4779166.2. Gültepe İ, **Başaranoğlu M**, Zorlu M, Şenyiğit A, Taşkale EZ, Zaralı S, Atay K, Köroğlu E. Low lipase levels as an independent marker of pancreatic cancer: a frequently neglected condition in clinical setting. *Turk J Gastroenterol.* 2016 Mar;27(2):197-200. doi: 10.5152/tjg.2016.16056. PubMed PMID: 27015625.3. İlhami Gültepe, **Metin Basaranoglu**, Yaser Suleymanoglu, Gokcen Basaranoglu and Fatma Beyazit. Ovaries are more vulnerable than hepatocytes for insulin resistance and hyperinsulinemia. *Turk J Gastroenterol.* 2016 Jan;27(1):62-7. doi: 10.5152/tjg.2015.150473. PubMed PMID: 26728862.4. Kayaçetin S, **Başaranoğlu M**. Mallory-Denk bodies: Correlation with steatosis, severity, zonal distribution, and identification with ubiquitin. *Turk J Gastroenterol.* 2015 Nov;26(6):506-10. doi: 10.5152/tjg.2015.150199. 5. Hardalaç F, **Başaranoğlu M**, Yüksel M, Kutbay U, Kaplan M, Özderin Özin Y, Kılıç ZM, Demirbağ AE, Coşkun O, Aksoy A, Gangarapu V, Örmeci N, Kayaçetin E. The rate of mucosal healing by azathioprine therapy and prediction by artificial systems. *Turk J Gastroenterol.* 2015 Jul;26(4):315-21. doi: 10.5152/tjg.2015.0199. 6. **Basaranoglu M**, Canbakan B, Yıldız K, Ceylan B, Baysal B, Uysal O, Senturk H. Nonalcoholic fatty liver may increase the risk of operation in patients with fatty liver and the frequency of cancer in their first-degree relatives. *Wien Klin Wochenschr.* 2015 Apr 14. [Epub ahead of print] PubMed PMID: 25869759.7. **Basaranoglu M**, Sayilir A, Demirbag AE, Mathew S, Ala A, Senturk H. Seasonal clustering in inflammatory bowel disease: a single centre experience. *Expert Rev Gastroenterol Hepatol.* 2015 Mar 19:1-5. [Epub ahead of print] PubMed PMID: 25790731.8. Kalem F, Yüksekaya S, **Başaranoğlu M**. The seroprevalence of both hepatitis B and hepatitis C at the first-step health organizations and the difference between the urban and rural areas. *Wien Klin Wochenschr.* 2015 Apr 14. [Epub ahead of print] PubMed PMID: 25869760.9. **Başaranoğlu M**, Sayılır A, Yüksel M, Yıldız H, Suvak B, Turhan N, Tunç B, Özin Y. Characterization of de novo colonic stricture due to Crohn's disease. *Turk J Gastroenterol.* 2014 Dec;25 Suppl 1:S129-32. doi: 10.5152/tjg.2014.7677. PubMed PMID: 25910290.10. Ceylan B, Fincanci M, Muderrisoglu C, Soysal F, Eren G, and **Basaranoglu M**. Variables determining the virological response to adefovir treatment in patients with chronic HBV infection previously treated with lamivudine. *African Journal of Microbiology Research.* 1-6;7(1) 2013. DOI:10.5897. AJMR/12.031.11. Neuschwander-Tetri BA, Ford DA, Acharya S, Gilkey G, **Basaranoglu M**, Tetri LH, Brunt EM. Dietary trans-fatty acid induced NASH is normalized following loss of trans-fatty acids from hepatic lipid pools. *Lipids.* 2012 Oct;47(10):941-50. PubMed PMID: 22923371; PubMed Central PMCID: PMC3473077. 12. Yilmaz UE, Yilmaz N, Titiz I, **Basaranoglu M**, Tarcin O. The utility of amylase and lipase as reliable predictive markers for functioning renal graft. *Ann Transplant.* 2012 Jul-Sep;17(3):77-84. PubMed PMID: 23018259. 13. Dellinger EP, Forsmark CE, Layer P, Lévy P, Maraví-Poma E, Petrov MS, Shimosegawa T, Siriwardena AK, Uomo G, Whitcomb DC, Windsor JA; **Basaranoglu M**, Pancreatitis Across Nations Clinical Research and Education Alliance (PANCREA). Determinant-Based Classification of Acute Pancreatitis Severity: An International Multidisciplinary Consultation. *Ann Surg.* 2012 Dec;256(6):875-

880. PubMed PMID: 22735715.14. Tarcin O, **Basaranoglu M**, Tahan V, Tahan G, Sücüllü I, Yilmaz N, Sood G, Snyder N, Hilman G, Celikel C, Tözün N. Time course of collagen peak in bile duct-ligated rats. *BMC Gastroenterology*. 2011 Apr 28;11:45. 15. Eren OO, Artac M, Boruban MC, Yavas O, Arslan U, Basaranoglu M. Chemotherapy-induced Hepatitis B virus reactivation in HbsAg positive cancer patients: a single center experience. *Med Oncol*. 2009 Dec 26 (4):386-92. 16. Tetri LH, **Basaranoglu M**, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. *Am J Physiol Gastrointest Liver Physiol*. 2008Nov;295(5):G987-95. 17. Basaranoglu M et al. Prevalence and Consultation Behavior of Self-Reported Rectal Bleeding by Face-to-Face Interview in an Asian Community. *Digestion*. 2008 Jan 30;77(1):10-15. 18. Demirkok SS, **Basaranoglu M**, Coker E, Karayel T. Seasonality of the onset of symptoms, tuberculin test anergy and Kveim positive reaction in a large cohort of patients with sarcoidosis. *Respirology*. 2007;12:591-3. 19. Demirkok SS, **Basaranoglu M**, Akinci ED, Karayel T. Analysis of 275 patients with sarcoidosis over a 38 year period; a single-institution experience. *Respir Med*. 2007;101:1147-54. 20. Sipahi Demirkok S, **Basaranoglu M**, Dervis E, Bal M, Karayel T. Analysis of 87 patients with Löfgren's syndrome and the pattern of seasonality of subacute sarcoidosis. *Respirology*. 2006;11:456-61. 21. Demirkok SS, **Basaranoglu M**, Akbilgic O. Seasonal variation of the onset of presentations in stage 1 sarcoidosis. *Int J Clin Pract*. 2006 Nov;60(11):1443-50. 22. G Basaranoglu, **Basaranoglu M**, et al. The effects of valsalva manoeuvres on venopuncture pain. *ÜrJ Anaesthesiol*. 2006;23:591-3.

REVIEWS

NAFLD: 1-4, 6-9

ANKAFERD: 5

1. **Basaranoglu M**, Basaranoglu G, Bugianesi E. Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction. *Hepatobiliary Surg Nutr*. 2015 Apr;4(2):109-16. doi: 10.3978/j.issn.2304-3881.2014.11.05. Review. PubMed PMID: 26005677 Central PMCID: PMC4405421. 2. **Basaranoglu M** and Ormeci N. Nonalcoholic fatty liver disease: Diagnosis, pathogenesis, and management. *The Turkish Journal of Gastroenterology*. Accepted for publication in 2014.3. **Basaranoglu M**, Basaranoglu G, Sabuncu T, Sentürk H. Fructose as a key player in the development of fatty liver disease. *World J Gastroenterol*. 2013 Feb 28;19(8):1166-72. doi: 10.3748/wjg.v19.i8.1166. PubMed PMID: 23482247; PubMed Central PMCID: PMC3587472. Cited by 134. **Basaranoglu M**, Basaranoglu G, Sentürk H. From fatty liver to fibrosis: A tale of "second hit". *World J Gastroenterol*. 2013 Feb 28;19(8):1158-65. doi: 10.3748/wjg.v19.i8.1158. PubMed PMID: 23483818; PubMed Central PMCID: PMC3587471. Cited by 85. Yavuz B, Kekkilli M, Haznedaroglu IC, Kayacetin E and **Basaranoglu M**. Ankaferd Blood Stopper in the management of gastrointestinal bleeding diseases. *World J Gastroenterol*. 2011 Sep 21;17(35):3962-70. Cited by 86. **Basaranoglu M**, Turhan N, Sonsuz A, Basaranoglu G. Mallory Denk Bodies in chronic liver diseases. *World J Gastroenterol*. 2011 May 7;17(17):2172-7. Cited by 37. **Basaranoglu M** and Basaranoglu G. Pathophysiology of insulin resistance and steatosis in patients with chronic viral hepatitis. *World J Gastroenterol*. 2011 Sep 28;17(36):4055-62.8. **Basaranoglu M**, Kayacetin S, Yilmaz N, Kayacetin E, Tarcin O, Sonsuz A. Understanding mechanisms of the pathogenesis of nonalcoholic fatty liver disease. *World J Gastroenterol*. 2010 May 14;16(18):2223-6. 9. **Basaranoglu M** and Neuschwander-Tetri Brent A. *Nonalcoholic Fatty Liver Disease: Clinical Features and Pathogenesis*. *Gastroenterology & Hepatology*. 2006;2:282-291.

EDITORIALS, LETTERS, MISCELLANEOUS:

1. **Basaranoglu M**, O Acbay, and A Sonsuz. A controlled trial of gemfibrozil in the treatment of patients with NASH. *J Hepatol*. 1999; 31: 384. 2. Ipekci S, **Basaranoglu M**, et al. The fluctuation of serum levels of aminotransferase in patients with nonalcoholic steatohepatitis. *J Clin Gastroenterol*. 2003;4:371. 3. **Basaranoglu M**. Serum levels of triglyceride and insulin resistance in patients with NASH. *Can J Gastroenterol*. 2002;16:813-4. 4. Sonsuz A, **Basaranoglu M**, et al. Hyperinsulinemia in nondiabetic, both obese and nonobese patients with nonalcoholic steatohepatitis. *Am J Gastroenterol*. 2002;97:495. 5. **Basaranoglu M**, A Sonsuz et al. The low incidence of primary liver disease in patients with nonalcoholic steatohepatitis. *J Hepatol*. 2001;35:684-5. 6. Sonsuz A, **Basaranoglu M**, et al. Relationship between aminotransferase levels and histopathological findings in patients with nonalcoholic steatohepatitis. *Am J Gastroenterol*. 2000;95:1370-16. 7. **Basaranoglu M** et al. Considerations in

seasonal variation studies in IBD and re-evaluation of Aratari et al.'s seasonality results. *Dig Liver Dis.* 2006 Sep;38(9):710-1. 8. **Basaranoglu M.** Symptom date is better than the endoscopic diagnosis date in seasonal variation studies in IBD. *Am J Gastroenterol.* 2006 Nov;101(11):2668-9.

E – Case reports:

9. **Basaranoglu M,** Balci NC. A true fundic diverticulum of the gallbladder. *J Gastroenterol Hepatol.* 2006 Jul;21(7):1222-3. 10. **Basaranoglu M,** Balci NC, Klor HU. Gallbladder sludge and acute pancreatitis induced by acute hepatitis A. *Pancreatology.* 2006;6:141-4. 11. **Basaranoglu M,** Balci NC, Klor HU. Anomalous pancreaticobiliary junction (APBJ) with the drainage of the uncinate process into the minor papilla: demonstration by MRI. *Br J Radiol.* 2005;78:655-8. 12. **Basaranoglu M,** Balci NC. Recurrent cholangitis associated with biliary sludge and Phrygian cap anomaly diagnosed by magnetic resonance imaging and magnetic resonance cholangio-pancreatography despite normal ultrasound and computed tomography. *Scand J Gastroenterol.* 2005;40:736-40. 13. **Basaranoglu M,** **Basaranoglu M.** Behcet's disease complicated with celiac trunk aneurysm. *J Clin Gastroenterol.* 2001;33:174-5. 14. **Basaranoglu M,** et al. Spontaneous perirenal hematoma as the initial manifestation of polyarteritis nodosa and long-term follow-up without treatment. *Nephron.* 2000; 85: 279-80. 15. **Basaranoglu M,** et al. A case of familial Mediterranean fever and polyarteritis nodosa complicated by spontaneous bilateral perirenal and subcapsular splenic haemorrhage. *Rheumatology.* 1999;38:794-6. Cited by 616. **Basaranoglu M,** et al. A case of fibrosing mediastinitis with obstruction of superior vena cava and downhill esophageal varices: a rare cause of upper gastrointestinal hemorrhage. *J Clin Gastroenterol.* 1999; 28: 268-70. 17. **Basaranoglu M,** et al. A case of cervical Brucella spondylitis with paravertebral abscess and neurological deficits. *Scand J Infect Dis.* 1999;31: 214-5. 18. Sonsuz A, **Basaranoglu M,** et al. Amebic abscess of the caudate lobe with spontaneous rupture into the biliary tract., *J Clin Gastroenterol.* 1998;26:355-6. 19. **Basaranoglu M,** et al. Primary pelvic hydatid cyst. *J Clin Gastroenterol.* 1998;26:157-8.

CONFERENCE PROCEEDINGS

1. **Basaranoglu M** et al. DIAGNOSTIC YIELD OF COLONOSCOPIC IMAGES AND BIOPSY RESULTS BY TUBERCULOSIS CULTURE (SOLID AND LIQUID) IN PATIENTS WITH INTESTINAL ULCERATION. European Chron's and Colitis Organization. February 2015.
 2. **Basaranoglu M et al.** Characteristics of 665 patients with esophageal varices. EASL monothematic conference. Innsbruck, Austria, 26-28 February, 2015.
 3. **Basaranoglu M, et al.** Percutaneous liver biopsy for Cholangiocarcinoma: As a single centre experience. APASL. Shanghai. March 2015
 4. **Basaranoglu M et al.** MIGRATED FISH BONE CAUSED LIVER ABSCESS PRESENTED AS A GASTROINTESTINAL STROMAL TUMOR DIAGNOSED BY ECHOENDOSCOPY. APASL. Shanghai. March 2015
 5. **Basaranoglu M,** et al. INCREASED FREQUENCY OF ENDOSCOPIC MUCOSAL HEALING AND REDUCED INTESTINAL RESECTION IN PATIENTS WITH SEVERE IBD BY LONGTERM AZATHIOPRINE THERAPY, BUT NEGATIVELY AFFECTED BY MALE GENDER. UEGW 18-22 October 2014, Vienna.
 6. **Basaranoglu M,** et al. INCREASED PREVALENCE OF CHRONIC LIVER AND PANCREAS ABNORMALITIES IN PATIENTS WITH CELIAC DISEASE. UEGW 18-22 October 2014, Vienna.
-
1. **Basaranoglu M,** Yüksel M, Ergün F, Kacar S. The prevalence of pancreas abnormalities in patients with inflammatory bowel disease was screened by US and further examined by EUS: not frequent, but also not rare! *Pancreatology*, Volume 14, Issue 3, S117. Combined EPC&IAP meeting. June 24-28, 2014. Southampton, UK.
 2. **Basaranoglu M,** Yüksel M, Yüceer C, Yildiz H, Bilge Z. Increased prevalence of chronic type pancreas paraneoplastic changes in patients with celiac disease characterized by echoendoscopy. *Pancreatology*, Volume 14, Issue 3, S41. Combined EPC&IAP meeting. June 24-28, 2014. Southampton, UK.
 3. Kacar S, Parlak E, Disibeyaz S, **Basaranoglu M** et al. Pancreas divisum: As a cause of chronic pancreatitis, even adenocarcinoma? *Pancreatology*, Volume 14, Issue 3, S104. Combined EPC&IAP meeting. June 24-28, 2014. Southampton, UK.

4. Kacar S, **Basaranoglu M** et al. Ulcerative colitis, Crohns disease, celiac disease and glucogen storage disease: As a cause of chronic pancreatitis in a small group of patients! Pancreatology, Volume 14 , Issue 3 , S117. Combined EPC&IAP meeting. June 24-28, 2014. Southampton, UK.
5. **Basaranoglu M** and Yüksel M. Increased prevalence of gallbladder&pancreas and lower GI tract abnormalities in patients with primary biliary cirrhosis. EASL Monothematic Conference in Primary Biliary Cirrhosis. 2014. May 23-4. Milan. Italy.
6. **Basaranoglu M**, Yüksel M, et al. Evaluation of undiagnosed liver masses, not exhibit typical features but HCC, even HCC with stage C. The 3th world congress on controversies in the menagement of viral hepatitis (C- Hep), EASL 2014. May 1-3. Berlin. Germany.
7. **Kacar S, Basaranoglu M et al. Paranchymal changes of the pancreas in patients with IBD was not frequent among the patients with chronic pancreatitis.** Falk Meeting. May 29-31, 2014. Paris, France.
8. **Basaranoglu M**, Yüksel M, et al. The prevalence of liver, biliary tract and pancreas abnormalities in patients with inflammatory bowel disease screened by US: not frequent, but also not rare. Falk Meeting. May 29-31, 2014. Paris, France.
9. **Taskiran I, Basaranoglu M**, et al. **Characterization of 41 PSC patients with IBD and long-term follow-up results.** Falk Meeting. May 29-31, 2014. Paris, France.
10. **Basaranoglu M, et al.** Long term follow-up results of 14 IBD patients with PSC&dominant stricture. **9th Congress of ECCO – Inflammatory Bowel Diseases February 20-22, 2014 in Copenhagen, Denmark.**
11. **Basaranoglu M, et al.** Proctocolectomy-ileal pouch-anal anastomosis for ulcerative colitis may increase prevalence of primary sclerosing cholangitis with dominant stricture in a short period like 24 months. **9th Congress of ECCO – Inflammatory Bowel Diseases February 20-22, 2014 in Copenhagen, Denmark.**
12. **Basaranoglu M, et al.** Increased beta cell function in patients with NAFLD and PCO. Scientific Program of Gastro 2013 APDW/WCOG Shanghai.
13. **Basaranoglu M, et al.** Crohn’s Disease diagnosed by double balloon enteroscopy. Scientific Program of Gastro 2013 APDW/WCOG Shanghai.
14. **Basaranoglu M, et al.** Colonic strictures due to CD treated by 18 months adalimumab injection therapy. Scientific Program of Gastro 2013 APDW/WCOG Shanghai.
15. **Basaranoglu M, et al. Is there a delay on health care seeking in patients with IBD.** Scientific Program of Gastro 2013 APDW/WCOG Shanghai.
16. **Basaranoglu M**, Binnur Canbakan, Kemal Yildiz, Bahadır Ceylan, Birol Baysal, Hakan Sentürk. Whether the existence of fat in the liver increases the risk of cancer and operation. AASLD annual meeting. November 2012, Boston, USA.
17. **Kalem F, Basaranoglu M.** The seroprevalance of HBV and HCV at the first step health organizations and urban vs rural areas. Falk Meeting. October 1-6, 2012. London, UK.
18. **Ince AT, Danahoglu A, Yildiz K, Cinar A, Basaranoglu M, Sentürk H. Home treatment of patients with acute pancreatitis: a preliminary report. UEGW. October, 2012.**
19. Zülfikar Polat, Ahmet Uygun, **Basaranoglu M**, Fatih Aslan, Nuri Ercin, Gürkan Celebi, Mustafa Gülsen, Sait Bağcı. TWEAK in the mechanism of development of nonalcoholic fatty liver disease. Controversises in gastroenterology. Falk Meeting. October 4-6, 2012. Mainz Germany.
20. Bahadır Ceylan, Muzaffer Fincanci, Cuneyt Muderrisoglu, Ferda Soysal, Gulhan Eren, and **Basaranoglu M.** Long term follow-up of patients with anti-hepatitis D antibody. Controversises in gastroenterology. Falk Meeting. October 4-6, 2012. Mainz Germany.
21. Kalem F, Özdemir M, **Basaranoglu M**, Toy H, Baysal B. Helicobacter pylori isolates recovered from antral gastric biopsies of patients with dyspeptic symptoms: antimicrobial resistance of metronidazole, clarithromycin and amoxicillin. Controversises in gastroenterology. Falk Meeting. October 2-4, 2012. Mainz Germany.
22. Bahadır Ceylan, Muzaffer Fincanci, Cuneyt Muderrisoglu, Ferda Soysal, Gulhan Eren, and **Basaranoglu M.** The variables predicting the virological response and resistance to adefovir therapy in cases with chronic hepatitis b. Controversises in gastroenterology. Falk Meeting. October 2-4, 2012. Mainz Germany.
23. Bahadır Ceylan, Muzaffer Fincanci, Cuneyt Muderrisoglu, Ferda Soysal, Gulhan Eren, and **Basaranoglu M.** Predictors of liver fibrosis in patients with chronic hepatitis c virus infection. Controversises in gastroenterology. Falk Meeting. October 2-4, 2012. Mainz Germany.

24. Kemal Yildiz, Mukaddes Tozlu, Ali Tüzün Ince, Orhan Kocaman, Birol Baysal, **Basaranoglu M.** Hakan Sentürk. A Giant Left Adrenal Pseudocyst Diagnosed by Echoendoscopy & Laparoscopic Adrenalectomy Performed. Controversies in gastroenterology. Falk Meeting. October 2-4, 2012. Mainz Germany.
25. **Beyazit Y, Sayilir A, Basaranoglu M. Increased ace in extrahepatic cholangiocarcinoma as a clue for activated ras in biliary neoplasms. UEGW. 21-26 October, 2011. Sweden.**
26. Yavuz Beyazit, Turkey; Burak Suvak; Serkan Torun; Abdurrahim Sayilir; **Basaranoglu M.** Mean platelet volume as an indicator of disease severity in acute pancreatitis. **UEGW. 21-26 October, 2011. Sweden.**
27. **Basaranoglu M,** et al. Seasonal variations in patients with IBD with new onset of disease. Falk meeting. Bruxelles 2011.
28. **Basaranoglu M,** et al. Longterm follow-up in IBD patients with colonic stricture. Falk meeting. Bruxelles 2011.
29. **Basaranoglu M,** et al. Our results from Turkey. Ankaferd hemostat for the management of upper gastrointestinal hemorrhages. Falk Meeting 15-16 June 2011, Hannover, Germany.
30. Nessar G, **Basaranoglu M,** et al. Surgical management of obstructive Crohn's disease in adults: Long-term results of a tertiary referral center. Falk Meeting 15-16 April 2011, Berlin, Germany.
31. **Basaranoglu M,** Turhan T. Mallory Denk Bodies in chronic hepatitis and its importance. The 21st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2011)17-20 February 2011, QSNCC, Bangkok Thailand.
32. **Basaranoglu M,** et al. Ankaferd hemostat for the management of upper gastrointestinal hemorrhages: a metaanalysis. Falk Meeting 15-16 April 2011, Berlin, Germany.
33. **Basaranoglu M,** et al. Basic mechanism of Ankaferd Blood Stopper. Falk Meeting 15-16 April 2011, Berlin, Germany (bu çalışma ile 2. the best abstract award kazandık).
34. **Basaranoglu M et al.** Does the immunosuppression induce hcv chronicity ? Long term observation of kidney recipients. ETCO, European Organ Donation Congress. 24-26 September 2010 Cardiff Wales, UK.
35. **Basaranoglu M et al.** Predictive value of post-transplant amylase elevation on renal impairment; is amylase substituted to serum creatinine? ETCO, European Organ Donation Congress. 24-26 September 2010 Cardiff Wales, UK.
36. **Basaranoglu M, et al.** Prevalence and Consultation Behaviour of Self-Reported Rectal Bleeding by Face-to-Face Interview in an Asian Community. IGA-AGA Institute Joint Meeting. Tel Aviv. 7, 8 February 2008.
37. **Basaranoglu M,** et al. The prevalence and risk factors associated with post-infective irritable bowel syndrome (PI-IBS) developed in hospitalized patients due to acute bacterial gastroenteritis. IGA-AGA Institute Joint Meeting. Tel Aviv. 7, 8 February 2008.
38. Neuschwander-Tetri BA, **Basaranoglu M,** Lisa M. Yerian, Laura H. Tetri, Elizabeth M. Brunt. Resolution of hepatic steatosis despite persistent obesity in mice fed standard rodent chow after induction of type 2 NAFLD using the American Diet Induced Obesity Syndrome model. AASLD in Boston November 2007.
39. Tetri LH; Brunt EM; **Basaranoglu M;** Neuschwander-Tetri BA. Rapid onset of impaired glucose tolerance and pediatric type NAFLD in sedentary mice fed a fast-food type diet. In DDW, Washington, USA, May 2007.
40. **Basaranoglu M;** Tetri, LH; Brunt EM; Neuschwander-Tetri, BA. Paradoxical Changes in Insulin Tolerance in Mice with NAFLD Induced by Sedentary Activity and an American Fast Food Type Diet. In CSCR/MWAFMR 2007 Annual Meeting, Chicago, USA, April 2007.
41. **Basaranoglu M,** Özbay G, Caldwell SH, et al. Refinement of a clinicopathological typing system for NAFL. AASLD in Boston, Oct-Nov 2003.
42. Ipekci S, **Basaranoglu M,** et al. The fluctuation of serum levels of aminotransferase in patients with nonalcoholic steatohepatitis. AASLD in Atlanta. 2002.
43. SS. Demirkok, **Basaranoglu M,** et al. Seasonal variation of the onset of presentations in patients with sarcoidosis presented with BHL alone. ERS. Denmark. 2005.
44. SS. Demirkok, **Basaranoglu M,** et al. Predicting the course of sarcoidosis with clinical factors. ERS. Denmark. 2005.
45. SS. Demirkok, **Basaranoglu M,** et al. Seasonal pattern in the onset of patients with sarcoidosis in Turkey. American Torasic Society Annual Meeting. 2005.

46. SS. Demirkok, **Basaranoglu M**, et al. Erythema nodosum due to sarcoidosis vs other causes. American Torasic Society Annual Meeting. 2005.
47. **Basaranoglu M**, et al. Serum levels of triglyceride and insulin resistance in patients with nonalcoholic steatohepatitis. AASLD single topic conference in Atlanta. 2002.
48. Özsine S, **Basaranoglu M**, et al. Sex and NASH. AASLD in Atlanta. 2002.
49. Sonsuz, A; **Basaranoglu M**; Bilir, M; Ozdemir, S; Ozbay, G; Senturk, H; Akin, P. Relationship between histopathologic findings and aminotransferase level patients with nonalcoholic steatohepatitis. Annual AASLD Meeting in Boston November 1998.
50. **Basaranoglu M**; Sonsuz, A; Bilir, M; Ozdemir, S; Acbay, O; Ozbay, G; Senturk, H; Akin, P. A controlled trial of gemfibrozil in the treatment of nonalcoholic steatohepatitis. Annual AASLD Meeting in Boston November 1998.